Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2014 (2014), Article ID 848632, 17 pages
http://dx.doi.org/10.1155/2014/848632
Review Article

Interaction of Dietary Fatty Acids with Tumour Necrosis Factor Family Cytokines during Colon Inflammation and Cancer

1Department of Cytokinetics, Institute of Biophysics, Academy of Sciences of the Czech Republic, v.v.i., Královopolská 135, 612 65 Brno, Czech Republic
2Institute of Experimental Biology, Department of Animal Physiology and Immunology, Faculty of Science, Masaryk University, Kotlářská 2, 611 37 Brno, Czech Republic

Received 14 February 2014; Accepted 29 March 2014; Published 30 April 2014

Academic Editor: Arkadiusz Orzechowski

Copyright © 2014 Jiřina Hofmanová et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. E. Bertrand, C. W. Angus, W. J. Partis, and G. Sigounas, “Developmental pathways in colon cancer: crosstalk between WNT, BMP, Hedgehog and Notch,” Cell Cycle, vol. 11, pp. 4344–4351, 2012. View at Google Scholar
  2. C. Gunther, H. Neumann, M. F. Neurath, and C. Becker, “Apoptosis, necrosis and necroptosis: cell death regulation in the intestinal epithelium,” Gut, vol. 62, pp. 1062–1071, 2013. View at Google Scholar
  3. F. E. Ahmed, “Colon cancer: prevalence, screening, gene expression and mutation, and risk factors and assessment,” Journal of Environmental Science and Health C: Environmental Carcinogenesis and Ecotoxicology Reviews, vol. 21, no. 2, pp. 65–131, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. W. M. Grady and J. M. Carethers, “Genomic and epigenetic instability in colorectal cancer pathogenesis,” Gastroenterology, vol. 135, no. 4, pp. 1079–1099, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Lifshitz, S. A. Lamprecht, D. Benharroch, I. Prinsloo, S. Polak-Charcon, and B. Schwartz, “Apoptosis (programmed cell death) in colonic cells: from normal to transformed stage,” Cancer Letters, vol. 163, no. 2, pp. 229–238, 2001. View at Publisher · View at Google Scholar · View at Scopus
  6. B. Zhivotovsky and S. Orrenius, “Carcinogenesis and apoptosis: paradigms and paradoxes,” Carcinogenesis, vol. 27, no. 10, pp. 1939–1945, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. L. Chen, S. M. Park, A. V. Tumanov et al., “CD95 promotes tumour growth,” Nature, vol. 465, pp. 492–496, 2010. View at Google Scholar
  8. F. Balkwill and A. Mantovani, “Inflammation and cancer: back to Virchow?” The Lancet, vol. 357, no. 9255, pp. 539–545, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. P. L. Lakatos and L. Lakatos, “Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies,” World Journal of Gastroenterology, vol. 14, no. 25, pp. 3937–3947, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. S. H. Itzkowitz and X. Yio, “Inflammation and cancer—IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation,” American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 287, no. 1, pp. G7–G17, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. U. Gaur and B. B. Aggarwal, “Regulation of proliferation, survival and apoptosis by members of the TNF superfamily,” Biochemical Pharmacology, vol. 66, no. 8, pp. 1403–1408, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. P. Boyle and M. E. Leon, “Epidemiology of colorectal cancer,” British Medical Bulletin, vol. 64, pp. 1–25, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. T. Yamamoto, M. Nakahigashi, and A. R. Saniabadi, “Review article: diet and inflammatory bowel disease—epidemiology and treatment,” Alimentary Pharmacology and Therapeutics, vol. 30, no. 2, pp. 99–112, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. M. F. McEntee and J. Whelan, “Dietary polyunsaturated fatty acids and colorectal neoplasia,” Biomedicine and Pharmacotherapy, vol. 56, no. 8, pp. 380–387, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. M. P. Weijenberg, M. Lüchtenborg, A. F. P. M. de Goeij et al., “Dietary fat and risk of colon and rectal cancer with aberrant MLH1 expression, APC or KRAS genes,” Cancer Causes and Control, vol. 18, no. 8, pp. 865–879, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. D. Schrenk, “Dietary fiber, low-molecular-weight food constituents and colo-rectal inflammation in animal models—a review,” Molecular Nutrition and Food Research, vol. 53, no. 10, pp. 1281–1288, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Putaala, H. Mäkivuokko, K. Tiihonen, and N. Rautonen, “Simulated colon fiber metabolome regulates genes involved in cell cycle, apoptosis, and energy metabolism in human colon cancer cells,” Molecular and Cellular Biochemistry, vol. 357, no. 1-2, pp. 235–245, 2011. View at Google Scholar · View at Scopus
  18. G. Sethi, M. K. Shanmugam, L. Ramachandran, A. P. Kumar, and V. Tergaonkar, “Multifaceted link between cancer and inflammation,” Bioscience Reports, vol. 32, no. 1, pp. 1–15, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. D. B. Vendramini-Costa and J. E. Carvalho, “Molecular link mechanisms between inflammation and cancer,” Current Pharmaceutical Design, vol. 18, pp. 3831–3852, 2012. View at Google Scholar
  20. T. Chiba, H. Marusawa, and T. Ushijima, “Inflammation-associated cancer development in digestive organs: mechanisms and roles for genetic and epigenetic modulation,” Gastroenterology, vol. 143, pp. 550–563, 2012. View at Google Scholar
  21. S. Danese and A. Mantovani, “Inflammatory bowel disease and intestinal cancer: a paradigm of the Yin-Yang interplay between inflammation and cancer,” Oncogene, vol. 29, no. 23, pp. 3313–3323, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. K. A. Tappenden, “Inflammation and intestinal function: where does it start and what does it mean?” Journal of Parenteral and Enteral Nutrition, vol. 32, no. 6, pp. 648–650, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Andoh, Y. Yagi, M. Shioya, A. Nishida, T. Tsujikawa, and Y. Fujiyama, “Mucosal cytokine network in inflammatory bowel disease,” World Journal of Gastroenterology, vol. 14, no. 33, pp. 5154–5161, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Kraus and N. Arber, “Inflammation and colorectal cancer,” Current Opinion in Pharmacology, vol. 9, no. 4, pp. 405–410, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. L. Klampfer, “Cytokines, inflammation and colon cancer,” Current Cancer Drug Targets, vol. 11, no. 4, pp. 451–464, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. G. Monteleone, F. Pallone, and C. Stolfi, “The dual role of inflammation in colon carcinogenesis,” International Journal of Molecular Sciences, vol. 13, pp. 11071–11084, 2012. View at Google Scholar
  27. A. Rizzo, F. Pallone, G. Monteleone, and M. C. Fantini, “Intestinal inflammation and colorectal cancer: a doubleedged sword?” World Journal of Gastroenterology, vol. 17, no. 26, pp. 3092–3100, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. B. K. Popivanova, K. Kitamura, Y. Wu et al., “Blocking TNF-α in mice reduces colorectal carcinogenesis associated with chronic colitis,” The Journal of Clinical Investigation, vol. 118, no. 2, pp. 560–570, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. M. J. Waldner and M. F. Neurath, “Cytokines in colitis-associated cancer: potential drug targets?” Inflammation and Allergy—Drug Targets, vol. 7, no. 3, pp. 187–194, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. S. R. Yan, R. R. Joseph, K. Rosen et al., “Activation of NF-κB following detachment delays apoptosis in intestinal epithelial cells,” Oncogene, vol. 24, no. 43, pp. 6482–6491, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. R. S. Chapkin, L. A. Davidson, L. Ly, B. R. Weeks, J. R. Lupton, and D. N. McMurray, “Immunomodulatory effects of (n-3) fatty acids: putative link to inflammation and colon cancer,” Journal of Nutrition, vol. 137, no. 1, pp. 200S–204S, 2007. View at Google Scholar · View at Scopus
  32. J. L. McClellan, J. M. Davis, J. L. Steiner et al., “Intestinal inflammatory cytokine response in relation to tumorigenesis in the ApcMin/+ mouse,” Cytokine, vol. 57, no. 1, pp. 113–119, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. B. B. Aggarwal, S. C. Gupta, and J. H. Kim, “Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey,” Blood, vol. 119, no. 3, pp. 651–665, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Bhardwaj and B. B. Aggarwal, “Receptor-mediated choreography of life and death,” Journal of Clinical Immunology, vol. 23, no. 5, pp. 317–332, 2003. View at Publisher · View at Google Scholar · View at Scopus
  35. H. Walczak and P. H. Krammer, “The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems,” Experimental Cell Research, vol. 256, no. 1, pp. 58–66, 2000. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Nagata, “Apoptosis by death factor,” Cell, vol. 88, no. 3, pp. 355–365, 1997. View at Publisher · View at Google Scholar · View at Scopus
  37. M. MacFarlane, “TRAIL-induced signalling and apoptosis,” Toxicology Letters, vol. 139, no. 2-3, pp. 89–97, 2003. View at Publisher · View at Google Scholar · View at Scopus
  38. N. Özören and W. S. El-Deiry, “Defining characteristics of types I and II apoptotic cells in response to TRAIL,” Neoplasia, vol. 4, no. 6, pp. 551–557, 2002. View at Publisher · View at Google Scholar · View at Scopus
  39. M. R. Sprick and H. Walczak, “The interplay between the Bcl-2 family and death receptor-mediated apoptosis,” Biochimica et Biophysica Acta, vol. 1644, no. 2-3, pp. 125–132, 2004. View at Publisher · View at Google Scholar · View at Scopus
  40. W. Wu, P. Liu, and J. Li, “Necroptosis: an emerging form of programmed cell death,” Critical Reviews in Oncology/Hematology, vol. 82, pp. 249–258, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. P. S. Welz, A. Wullaert, K. Vlantis et al., “FADD prevents RIP3-mediated epithelial cell necrosis and chronic intestinal inflammation,” Nature, vol. 477, no. 7364, pp. 330–334, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. B. Beutler and A. Cerami, “Cachectin and tumour necrosis factor as two sides of the same biological coin,” Nature, vol. 320, no. 6063, pp. 584–588, 1986. View at Google Scholar · View at Scopus
  43. M. Jäättelä, “Biology of disease: biologic activities and mechanisms of action of tumor necrosis factor-α/cachectin,” Laboratory Investigation, vol. 64, no. 6, pp. 724–742, 1991. View at Google Scholar · View at Scopus
  44. K. J. Tracey and A. Cerami, “Tumor necrosis factor: a pleiotropic cytokine and therapeutic target,” Annual Review of Medicine, vol. 45, pp. 491–503, 1994. View at Publisher · View at Google Scholar · View at Scopus
  45. H. C. Reinecker, M. Steffen, T. Witthoeft et al., “Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1β by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease,” Clinical and Experimental Immunology, vol. 94, no. 1, pp. 174–181, 1993. View at Google Scholar · View at Scopus
  46. C. Scheidereit, “IκB kinase complexes: gateways to NF-κB activation and transcription,” Oncogene, vol. 25, no. 51, pp. 6685–6705, 2006. View at Publisher · View at Google Scholar · View at Scopus
  47. A. Numata, T. Minagawa, M. Asano, A. Nakane, H. Katoh, and T. Tanabe, “Functional evaluation of tumor-infiltrating mononuclear cells: detection of endogenous interferon-γ and tumor necrosis factor-α in human colorectal adenocarcinomas,” Cancer, vol. 68, no. 9, pp. 1937–1943, 1991. View at Google Scholar · View at Scopus
  48. C. V. Zhang, Cell Apoptosis, Nova Science Publishers, Inc., New York, NY, USA, 2007.
  49. G. Mellier, S. Huang, K. Shenoy, and S. Pervaiz, “TRAILing death in cancer,” Molecular Aspects of Medicine, vol. 31, no. 1, pp. 93–112, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. S. R. Wiley, K. Schooley, P. J. Smolak et al., “Identification and characterization of a new member of the TNF family that induces apoptosis,” Immunity, vol. 3, no. 6, pp. 673–682, 1995. View at Publisher · View at Google Scholar · View at Scopus
  51. C. Falschlehner, U. Schaefer, and H. Walczak, “Following TRAIL's path in the immune system,” Immunology, vol. 127, no. 2, pp. 145–154, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. M. J. Mitchell, E. Wayne, K. Rana, C. B. Schaffer, and M. R. King, “TRAIL-coated leukocytes that kill cancer cells in the circulation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 111, pp. 930–935, 2014. View at Google Scholar
  53. A. Vaculova, V. Kaminskyy, E. Jalalvand, O. Surova, and B. Zhivotovsky, “Doxorubicin and etoposide sensitize small cell lung carcinoma cells expressing caspase-8 to TRAIL,” Molecular Cancer, vol. 9, article 87, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. P. Secchiero, A. Gonelli, E. Carnevale et al., “TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways,” Circulation, vol. 107, no. 17, pp. 2250–2256, 2003. View at Publisher · View at Google Scholar · View at Scopus
  55. A. Vaculová, J. Hofmanová, K. Souček, and A. Kozubík, “Different modulation of TRAIL-induced apoptosis by inhibition of pro-survival pathways in TRAIL-sensitive and TRAIL-resistant colon cancer cells,” FEBS Letters, vol. 580, no. 28-29, pp. 6565–6569, 2006. View at Publisher · View at Google Scholar · View at Scopus
  56. A. Vaculová, J. Hofmanová, J. Zatloukalová, and A. Kozubík, “Differences in TRAIL-induced changes of Mcl-1 expression among distinct human colon epithelial cell lines,” Experimental Cell Research, vol. 315, no. 19, pp. 3259–3266, 2009. View at Publisher · View at Google Scholar · View at Scopus
  57. D. A. Flusberg, J. Roux, S. L. Spencer, and P. K. Sorger, “Cells surviving fractional killing by TRAIL exhibit transient but sustainable resistance and inflammatory phenotypes,” Molecular Biology of the Cell, vol. 24, pp. 2186–2200, 2013. View at Google Scholar
  58. C. Falschlehner, C. H. Emmerich, B. Gerlach, and H. Walczak, “TRAIL signalling: decisions between life and death,” International Journal of Biochemistry and Cell Biology, vol. 39, no. 7-8, pp. 1462–1475, 2007. View at Publisher · View at Google Scholar · View at Scopus
  59. S. Brost, R. Koschny, J. Sykora et al., “Differential expression of the TRAIL/TRAIL-receptor system in patients with inflammatory bowel disease,” Pathology Research and Practice, vol. 206, no. 1, pp. 43–50, 2010. View at Publisher · View at Google Scholar · View at Scopus
  60. J. J. Koornstra, J. H. Kleibeuker, C. M. M. van Geelen et al., “Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas,” Journal of Pathology, vol. 200, no. 3, pp. 327–335, 2003. View at Publisher · View at Google Scholar · View at Scopus
  61. L. M. Laguinge, R. N. Samara, W. Wang et al., “DR5 receptor mediates anoikis in human colorectal carcinoma cell lines,” Cancer Research, vol. 68, no. 3, pp. 909–917, 2008. View at Publisher · View at Google Scholar · View at Scopus
  62. A. Grosse-Wilde, O. Voloshanenko, S. Lawrence Bailey et al., “TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development,” The Journal of Clinical Investigation, vol. 118, no. 1, pp. 100–110, 2008. View at Publisher · View at Google Scholar · View at Scopus
  63. F. J. H. Hoogwater, M. W. Nijkamp, N. Smakman et al., “Oncogenic K-Ras turns death receptors into metastasis-promoting receptors in human and mouse colorectal cancer cells,” Gastroenterology, vol. 138, no. 7, pp. 2357–2367, 2010. View at Publisher · View at Google Scholar · View at Scopus
  64. A. Hague, D. J. Hicks, F. Hasan et al., “Increased sensitivity to TRAIL-induced apoptosis occurs during the adenoma to carcinoma transition of colorectal carcinogenesis,” British Journal of Cancer, vol. 92, no. 4, pp. 736–742, 2005. View at Publisher · View at Google Scholar · View at Scopus
  65. J. Hofmanová, A. Vaculová, M. Hyžd’alová, and A. Kozubík, “Response of normal and colon cancer epithelial cells to TNF-family apoptotic inducers,” Oncology Reports, vol. 19, pp. 567–573, 2008. View at Google Scholar
  66. P. H. Krammer, R. Arnold, and I. N. Lavrik, “Life and death in peripheral T cells,” Nature Reviews Immunology, vol. 7, no. 7, pp. 532–542, 2007. View at Publisher · View at Google Scholar · View at Scopus
  67. S. I. Abrams, “Positive and negative consequences of Fas/Fas ligand interactions in the antitumor response,” Frontiers in Bioscience, vol. 10, pp. 809–821, 2005. View at Google Scholar · View at Scopus
  68. I. N. Lavrik and P. H. Krammer, “Regulation of CD95/Fas signaling at the DISC,” Cell Death and Differentiation, vol. 19, no. 1, pp. 36–41, 2012. View at Publisher · View at Google Scholar · View at Scopus
  69. M. A. Zimmerman, N. Singh, P. M. Martin et al., “Butyrate suppresses colonic inflammation through HDAC1-dependent Fas upregulation and Fas-mediated apoptosis of T cells,” American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 302, no. 12, pp. G1405–G1415, 2012. View at Publisher · View at Google Scholar
  70. Broad Institute, 2014, http://www.broadinstitute.org/tumorscape/pages/portalHome.jsf.
  71. C. Ruiz-Ruiz, G. Robledo, E. Cano, J. M. Redondo, and A. Lopez-Rivas, “Characterization of p53-mediated up-regulation of CD95 gene expression upon genotoxic treatment in human breast tumor cells,” The Journal of Biological Chemistry, vol. 278, no. 34, pp. 31667–31675, 2003. View at Publisher · View at Google Scholar · View at Scopus
  72. A. V. Paschall, M. A. Zimmerman, C. M. Torres et al., “Ceramide targets xIAP and cIAP1 to sensitize metastatic colon and breast cancer cells to apoptosis induction to suppress tumor progression,” BMC Cancer, vol. 14, article 24, 2014. View at Publisher · View at Google Scholar
  73. F. A. Sayani, C. M. Keenan, M. D. van Sickle et al., “The expression and role of Fas ligand in intestinal inflammation,” Neurogastroenterology and Motility, vol. 16, no. 1, pp. 61–74, 2004. View at Publisher · View at Google Scholar · View at Scopus
  74. J. P. Medema, J. de Jong, T. van Hall, C. J. M. Melief, and R. Offringa, “Immune escape of tumors in vivo by expression of cellular FLICE- inhibitory protein,” Journal of Experimental Medicine, vol. 190, no. 7, pp. 1033–1038, 1999. View at Publisher · View at Google Scholar · View at Scopus
  75. N. Wittkopf, C. Gunther, E. Martini et al., “Cellular FLICE-like inhibitory protein secures intestinal epithelial cell survival and immune homeostasis by regulating caspase-8,” Gastroenterology, vol. 145, no. 6, pp. 1369–1379, 2013. View at Publisher · View at Google Scholar
  76. F. Liu, K. Bardhan, D. Yang et al., “NF-kappaB directly regulates Fas transcription to modulate Fas-mediated apoptosis and tumor suppression,” The Journal of Biological Chemistry, vol. 287, pp. 25530–25540, 2012. View at Google Scholar
  77. A. P. Simopoulos, “Omega-3 fatty acids in health and disease and in growth and development,” American Journal of Clinical Nutrition, vol. 54, no. 3, pp. 438–463, 1991. View at Google Scholar · View at Scopus
  78. P. Matafome, D. Santos-Silva, C. M. Sena, and R. Seica, “Common mechanisms of dysfunctional adipose tissue and obesity-related cancers,” Diabetes/Metabolism Research and Reviews, vol. 29, no. 4, pp. 285–295, 2013. View at Publisher · View at Google Scholar
  79. S. D. Day, R. T. Enos, J. L. McClellan, J. L. Steiner, K. T. Velazquez, and E. A. Murphy, “Linking inflammation to tumorigenesis in a mouse model of high-fat-diet-enhanced colon cancer,” Cytokine, vol. 64, pp. 454–462, 2013. View at Google Scholar
  80. A. E. Tammariello and J. A. Milner, “Mouse models for unraveling the importance of diet in colon cancer prevention,” Journal of Nutritional Biochemistry, vol. 21, no. 2, pp. 77–88, 2010. View at Publisher · View at Google Scholar · View at Scopus
  81. H. Zeng and D. L. Lazarova, “Obesity-related colon cancer: dietary factors and their mechanisms of anticancer action,” Clinical and Experimental Pharmacology and Physiology, vol. 39, no. 2, pp. 161–167, 2012. View at Publisher · View at Google Scholar · View at Scopus
  82. P. Flachs, M. Rossmeisl, M. Bryhn, and J. Kopecky, “Cellular and molecular effects of n-3 polyunsaturated fatty acids on adipose tissue biology and metabolism,” Clinical Science, vol. 116, no. 1, pp. 1–16, 2009. View at Publisher · View at Google Scholar · View at Scopus
  83. A. P. Simopoulos, “Genetic variants in the metabolism of omega-6 and omega-3 fatty acids: their role in the determination of nutritional requirements and chronic disease risk,” Experimental Biology and Medicine, vol. 235, no. 7, pp. 785–795, 2010. View at Publisher · View at Google Scholar · View at Scopus
  84. A. P. Simopoulos, “The importance of the ratio of omega-6/omega-3 essential fatty acids,” Biomedicine and Pharmacotherapy, vol. 56, no. 8, pp. 365–379, 2002. View at Publisher · View at Google Scholar · View at Scopus
  85. J. X. Kang, “Balance of omega-6/omega-3 essential fatty acids is important for health. The evidence from gene transfer studies,” World Review of Nutrition and Dietetics, vol. 95, pp. 93–102, 2005. View at Google Scholar · View at Scopus
  86. L. S. Kremmyda, E. Tvrzicka, B. Stankova, and A. Zak, “Fatty acids as biocompounds: their role in human metabolism, health and disease: a review—part 2: fatty acid physiological roles and applications in human health and disease,” Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, vol. 155, no. 3, pp. 195–218, 2011. View at Publisher · View at Google Scholar · View at Scopus
  87. M. D'Archivio, B. Scazzocchio, S. Giammarioli et al., “omega3-PUFAs exert anti-inflammatory activity in visceral adipocytes from colorectal cancer patients,” PLoS ONE, vol. 8, Article ID e77432, 2013. View at Google Scholar
  88. D. A. Los and N. Murata, “Membrane fluidity and its roles in the perception of environmental signals,” Biochimica et Biophysica Acta, vol. 1666, no. 1-2, pp. 142–157, 2004. View at Publisher · View at Google Scholar · View at Scopus
  89. F. A. Sinicrope and S. Gill, “Role of cyclooxygenase-2 in colorectal cancer,” Cancer and Metastasis Reviews, vol. 23, no. 1-2, pp. 63–75, 2004. View at Publisher · View at Google Scholar · View at Scopus
  90. A. Medeiros, C. Peres-Buzalaf, F. Fortino Verdan, and C. H. Serezani, “Prostaglandin E2 and the suppression of phagocyte innate immune responses in different organs,” Mediators of Inflammation, vol. 2012, Article ID 327568, 13 pages, 2012. View at Publisher · View at Google Scholar
  91. A. Barajas-Espinosa, F. Ochoa-Cortes, M. P. Moos, F. D. Ramirez, S. J. Vanner, and C. D. Funk, “Characterization of the cysteinyl leukotriene 2 receptor in novel expression sites of the gastrointestinal tract,” American Journal of Pathology, vol. 178, no. 6, pp. 2682–2689, 2011. View at Publisher · View at Google Scholar · View at Scopus
  92. G. Hawcroft, P. M. Loadman, A. Belluzzi, and M. A. Hull, “Effect of eicosapentaenoic acid on E-type prostaglandin synthesis and EP4 receptor signaling in human colorectal cancer cells,” Neoplasia, vol. 12, no. 8, pp. 618–627, 2010. View at Publisher · View at Google Scholar · View at Scopus
  93. C. N. Serhan and N. Chiang, “Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus,” British Journal of Pharmacology, vol. 153, supplement 1, pp. S200–S215, 2008. View at Publisher · View at Google Scholar · View at Scopus
  94. I. L. Rudolph, D. S. Kelley, K. C. Klasing, and K. L. Erickson, “Regulation of cellular differentiation and apoptosis by fatty acids and their metabolites,” Nutrition Research, vol. 21, no. 1-2, pp. 381–393, 2001. View at Publisher · View at Google Scholar · View at Scopus
  95. C. P. Diggle, “In vitro studies on the relationship between polyunsaturated fatty acids and cancer: tumour or tissue specific effects?” Progress in Lipid Research, vol. 41, no. 3, pp. 240–253, 2002. View at Publisher · View at Google Scholar · View at Scopus
  96. C. H. MacLean, S. J. Newberry, W. A. Mojica et al., “Effects of omega-3 fatty acids on cancer risk: a systematic review,” Journal of the American Medical Association, vol. 295, no. 4, pp. 403–415, 2006. View at Publisher · View at Google Scholar · View at Scopus
  97. M. A. Moyad, “An introduction to dietary/supplemental omega-3 fatty acids for general health and prevention—part II,” Urologic Oncology: Seminars and Original Investigations, vol. 23, no. 1, pp. 36–48, 2005. View at Publisher · View at Google Scholar · View at Scopus
  98. J. Hofmanová, K. Souček, A. Vaculová, and A. Kozubík, “Fatty acids in the modulation of reactive oxygen species balance in cancer,” in Oxidants in Biology: A Question of Balance, G. Valacchi and P. A. Davis, Eds., chapter 6, pp. 129–153, Springer, Dordrecht, The Netherlands, 2008. View at Publisher · View at Google Scholar
  99. F. Abir, S. Alva, D. L. Kaminski, and W. E. Longo, “The role of arachidonic acid regulatory enzymes in colorectal disease,” Diseases of the Colon and Rectum, vol. 48, no. 7, pp. 1471–1483, 2005. View at Publisher · View at Google Scholar · View at Scopus
  100. A. Lanas and F. Sopeña, “Nonsteroidal anti-inflammatory drugs and lower gastrointestinal complications,” Gastroenterology Clinics of North America, vol. 38, no. 2, pp. 333–352, 2009. View at Publisher · View at Google Scholar · View at Scopus
  101. J. E. Teitelbaum and W. Allan Walker, “Review: the role of omega 3 fatty acids in intestinal inflammation,” Journal of Nutritional Biochemistry, vol. 12, no. 1, pp. 21–32, 2001. View at Publisher · View at Google Scholar · View at Scopus
  102. D. H. Jho, S. M. Cole, E. M. Lee, and N. J. Espat, “Role of omega-3 fatty acid supplementation in inflammation and malignancy,” Integrative Cancer Therapies, vol. 3, no. 2, pp. 98–111, 2004. View at Publisher · View at Google Scholar · View at Scopus
  103. S. C. Mills, A. C. Windsor, and S. C. Knight, “The potential interactions between polyunsaturated fatty acids and colonic inflammatory processes,” Clinical and Experimental Immunology, vol. 142, no. 2, pp. 216–228, 2005. View at Publisher · View at Google Scholar · View at Scopus
  104. B. S. Reddy, C. Burill, and J. Rigotty, “Effect of diets high in ω-3 and ω6 fatty acids on initiation and postinitiation stages of colon carcinogenesis,” Cancer Research, vol. 51, no. 2, pp. 487–491, 1991. View at Google Scholar · View at Scopus
  105. L. A. Davidson, D. V. Nguyen, R. M. Hokanson et al., “Chemopreventive n-3 polyunsaturated fatty acids reprogram genetic signatures during colon cancer initiation and progression in the rat,” Cancer Research, vol. 64, no. 18, pp. 6797–6804, 2004. View at Publisher · View at Google Scholar · View at Scopus
  106. G. Calviello and S. Serini, Dietary Omega-3 Polyunsaturated Fatty Acids and Cancer, Springer, New York, NY, USA, 2010.
  107. C. A. Hudert, K. H. Weylandt, Y. Lu et al., “Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 30, pp. 11276–11281, 2006. View at Publisher · View at Google Scholar · View at Scopus
  108. R. S. Pardini, “Nutritional intervention with omega-3 fatty acids enhances tumor response to anti-neoplastic agents,” Chemico-Biological Interactions, vol. 162, no. 2, pp. 89–105, 2006. View at Publisher · View at Google Scholar · View at Scopus
  109. M. E. Surette, “The science behind dietary omega-3 fatty acids,” Canadian Medical Association Journal, vol. 178, no. 2, pp. 177–180, 2008. View at Publisher · View at Google Scholar · View at Scopus
  110. G. Calviello, S. Serini, E. Piccioni, and G. Pessina, “Antineoplastic effects of N-3 polyunsaturated fatty acids in combination with drugs and radiotherapy: preventive and therapeutic strategies,” Nutrition and Cancer, vol. 61, no. 3, pp. 287–301, 2009. View at Publisher · View at Google Scholar · View at Scopus
  111. F. de Carlo, T. R. Witte, W. E. Hardman, and P. P. Claudio, “Omega-3 eicosapentaenoic acid decreases CD133 colon cancer stem-like cell marker expression while increasing sensitivity to chemotherapy,” PLoS ONE, vol. 8, Article ID e69760, 2013. View at Google Scholar
  112. S. C. Larsson, M. Kumlin, M. Ingelman-Sundberg, and A. Wolk, “Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms,” American Journal of Clinical Nutrition, vol. 79, no. 6, pp. 935–945, 2004. View at Google Scholar · View at Scopus
  113. R. S. Chapkin, J. Seo, D. N. McMurray, and J. R. Lupton, “Mechanisms by which docosahexaenoic acid and related fatty acids reduce colon cancer risk and inflammatory disorders of the intestine,” Chemistry and Physics of Lipids, vol. 153, no. 1, pp. 14–23, 2008. View at Publisher · View at Google Scholar · View at Scopus
  114. B. Skender, A. H. Vaculová, and J. Hofmanová, “Docosahexaenoic fatty acid (DHA) in the regulation of colon cell growth and cell death: a review,” Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, vol. 156, no. 3, pp. 186–199, 2012. View at Publisher · View at Google Scholar
  115. M. M. Kaczmarczyk, M. J. Miller, and G. G. Freund, “The health benefits of dietary fiber: beyond the usual suspects of type 2 diabetes mellitus, cardiovascular disease and color cancer,” Metabolism: Clinical and Experimental, vol. 61, pp. 1058–1066, 2012. View at Publisher · View at Google Scholar · View at Scopus
  116. H. M. Hamer, D. Jonkers, K. Venema, S. Vanhoutvin, F. J. Troost, and R.-J. Brummer, “Review article: the role of butyrate on colonic function,” Alimentary Pharmacology and Therapeutics, vol. 27, no. 2, pp. 104–119, 2008. View at Publisher · View at Google Scholar · View at Scopus
  117. J. Hofmanová, A. Vaculová, and A. Kozubík, “Regulation of the metabolism of polyunsaturated fatty acids and butyrate in colon cancer cells,” Current Pharmaceutical Biotechnology, vol. 14, no. 3, pp. 274–288, 2013. View at Google Scholar
  118. X. Tong, L. Yin, and C. Giardina, “Butyrate suppresses Cox-2 activation in colon cancer cells through HDAC inhibition,” Biochemical and Biophysical Research Communications, vol. 317, no. 2, pp. 463–471, 2004. View at Publisher · View at Google Scholar · View at Scopus
  119. N. T. Ventham, N. A. Kennedy, E. R. Nimmo, and J. Satsangi, “Beyond gene discovery in inflammatory bowel disease: the emerging role of epigenetics,” Gastroenterology, vol. 145, pp. 293–308, 2013. View at Google Scholar
  120. M. C. Daroqui and L. H. Augenlicht, “Transcriptional attenuation in colon carcinoma cells in response to butyrate,” Cancer Prevention Research, vol. 3, no. 10, pp. 1292–1302, 2010. View at Publisher · View at Google Scholar · View at Scopus
  121. R. B. Canani, M. D. Costanzo, L. Leone, M. Pedata, R. Meli, and A. Calignano, “Potential beneficial effects of butyrate in intestinal and extraintestinal diseases,” World Journal of Gastroenterology, vol. 17, no. 12, pp. 1519–1528, 2011. View at Publisher · View at Google Scholar · View at Scopus
  122. V. Ganapathy, M. Thangaraju, E. Gopal et al., “Sodium-coupled monocarboxylate transporters in normal tissues and in cancer,” AAPS Journal, vol. 10, no. 1, pp. 193–199, 2008. View at Publisher · View at Google Scholar · View at Scopus
  123. S. I. Karaki, H. Tazoe, H. Hayashi et al., “Expression of the short-chain fatty acid receptor, GPR43, in the human colon,” Journal of Molecular Histology, vol. 39, no. 2, pp. 135–142, 2008. View at Publisher · View at Google Scholar · View at Scopus
  124. R. Thibault, F. Blachier, B. Darcy-Vrillon, P. de Coppet, A. Bourreille, and J.-P. Segain, “Butyrate utilization by the colonic mucosa in inflammatory bowel diseases: a transport deficiency,” Inflammatory Bowel Diseases, vol. 16, no. 4, pp. 684–695, 2010. View at Publisher · View at Google Scholar · View at Scopus
  125. M. Andriamihaja, C. Chaumontet, D. Tome, and F. Blachier, “Butyrate metabolism in human colon carcinoma cells: implications concerning its growth-inhibitory effect,” Journal of Cellular Physiology, vol. 218, no. 1, pp. 58–65, 2009. View at Publisher · View at Google Scholar · View at Scopus
  126. J. Vondráček, M. A. Sheard, P. Krejčí, K. Minksová, J. Hofmanová, and A. Kozubík, “Modulation of death receptor-mediated apoptosis in differentiating human myeloid leukemia HL-60 cells,” Journal of Leukocyte Biology, vol. 69, pp. 794–802, 2001. View at Google Scholar
  127. J. Štika, J. Vondráček, J. Hofmanová, V. Šimek, and A. Kozubík, “MK-886 enhances tumour necrosis factor-alpha-induced differentiation and apoptosis,” Cancer Letters, vol. 237, pp. 263–271, 2006. View at Google Scholar
  128. J. Procházková, L. Stixová, K. Souček, J. Hofmanová, and A. Kozubík, “Monocytic differentiation of leukemic HL-60 cells induced by co-treatment with TNF-α and MK886 requires activation of pro-apoptotic machinery,” European Journal of Haematology, vol. 83, no. 1, pp. 35–47, 2009. View at Publisher · View at Google Scholar · View at Scopus
  129. M. Kovaříková, J. Hofmanová, K. Souček, and A. Kozubík, “The effects of TNF-α and inhibitors of arachidonic acid metabolism on human colon HT-29 cells depend on differentiation status,” Differentiation, vol. 72, no. 1, pp. 23–31, 2004. View at Publisher · View at Google Scholar · View at Scopus
  130. J. Hofmanová, A. Vaculová, and A. Kozubík, “Polyunsaturated fatty acids sensitize human colon adenocarcinoma HT-29 cells to death receptor-mediated apoptosis,” Cancer Letters, vol. 218, no. 1, pp. 33–41, 2005. View at Publisher · View at Google Scholar · View at Scopus
  131. A. Vaculová, J. Hofmanová, L. Anděra, and A. Kozubík, “TRAIL and docosahexaenoic acid cooperate to induce HT-29 colon cancer cell death,” Cancer Letters, vol. 229, pp. 43–48, 2005. View at Google Scholar
  132. O. Vondálová Blanářová, I. Jelínková, A. Szöor et al., “Cisplatin and a potent platinum(IV) complex-mediated enhancement of TRAIL-induced cancer cells killing is associated with modulation of upstream events in the extrinsic apoptotic pathway,” Carcinogenesis, vol. 32, no. 1, pp. 42–51, 2011. View at Google Scholar · View at Scopus
  133. J. Hofmanová, A. Vaculová, Z. Koubková, M. Hýžďalová, and A. Kozubík, “Human fetal colon cells and colon cancer cells respond differently to butyrate and PUFAs,” Molecular Nutrition & Food Research, vol. 53, supplement 1, pp. S102–S113, 2009. View at Google Scholar
  134. L. Kočí, M. Hýžd'alová, A. Vaculová, J. Hofmanová, and A. Kozubík, “Detachment-mediated resistance to TRAIL-induced apoptosis is associated with stimulation of the PI3K/Akt pathway in fetal and adenocarcinoma epithelial colon cells,” Cytokine, vol. 55, no. 1, pp. 34–39, 2011. View at Publisher · View at Google Scholar · View at Scopus
  135. M. T. Accioly, P. Pacheco, C. M. Maya-Monteiro et al., “Lipid bodies are reservoirs of cyclooxygenase-2 and sites of prostaglandin-E2 synthesis in colon cancer cells,” Cancer Research, vol. 68, no. 6, pp. 1732–1740, 2008. View at Publisher · View at Google Scholar · View at Scopus
  136. D. W. L. Ma, J. Seo, L. A. Davidson et al., “n-3 PUFA alter caveolae lipid composition and resident protein localization in mouse colon,” The FASEB Journal, vol. 18, no. 9, pp. 1040–1042, 2004. View at Publisher · View at Google Scholar · View at Scopus
  137. W. Stillwell, S. R. Shaikh, M. Zerouga, R. Siddiqui, and S. R. Wassal, “Docosahexaenoic acid affects cell signaling by altering lipid rafts,” Reproduction Nutrition Development, vol. 45, no. 5, pp. 559–579, 2005. View at Publisher · View at Google Scholar · View at Scopus
  138. J. Seo, R. Barhoumi, A. E. Johnson, J. R. Lupton, and R. S. Chapkin, “Docosahexaenoic acid selectively inhibits plasma membrane targeting of lipidated proteins,” The FASEB Journal, vol. 20, no. 6, pp. 770–772, 2006. View at Publisher · View at Google Scholar · View at Scopus
  139. K. R. Rogers, K. D. Kikawa, M. Mouradian et al., “Docosahexaenoic acid alters epidermal growth factor receptor-related signaling by disrupting its lipid raft association,” Carcinogenesis, vol. 31, no. 9, pp. 1523–1530, 2010. View at Publisher · View at Google Scholar · View at Scopus
  140. V. E. Kagan, Y. Y. Tyurina, H. Bayir et al., “The “pro-apoptotic genies” get out of mitochondria: oxidative lipidomics and redox activity of cytochrome c/cardiolipin complexes,” Chemico-Biological Interactions, vol. 163, no. 1-2, pp. 15–28, 2006. View at Publisher · View at Google Scholar · View at Scopus
  141. S. Rohrbach, “Effects of dietary polyunsaturated fatty acids on mitochondria,” Current Pharmaceutical Design, vol. 15, no. 36, pp. 4103–4116, 2009. View at Publisher · View at Google Scholar · View at Scopus
  142. M. Y. Hong, R. S. Chapkin, R. Barhoumi et al., “Fish oil increases mitochondrial phospholipid unsaturation, upregulating reactive oxygen species and apoptosis in rat colonocytes,” Carcinogenesis, vol. 23, no. 11, pp. 1919–1925, 2002. View at Google Scholar · View at Scopus
  143. K. Mbodji, C. Charpentier, C. Guerin et al., “Adjunct therapy of n-3 fatty acids to 5-ASA ameliorates inflammatory score and decreases NF-kappaB in rats with TNBS-induced colitis,” The Journal of Nutritional Biochemistry, vol. 24, pp. 700–705, 2013. View at Google Scholar
  144. C. Gravaghi, K. M. D. la Perle, P. Ogrodwski et al., “Cox-2 expression, PGE2 and cytokines production are inhibited by endogenously synthesized n-3 PUFAs in inflamed colon of fat-1 mice,” Journal of Nutritional Biochemistry, vol. 22, no. 4, pp. 360–365, 2011. View at Publisher · View at Google Scholar · View at Scopus
  145. A. Algamas-Dimantov, D. Davidovsky, J. Ben-Ari et al., “Amelioration of diabesity-induced colorectal ontogenesis by omega-3 fatty acids in mice,” The Journal of Lipid Research, vol. 53, pp. 1056–1070, 2012. View at Google Scholar
  146. S. N. Meydani, “Dietary modulation of cytokine production and biologic functions,” Nutrition Reviews, vol. 48, no. 10, pp. 361–369, 1990. View at Google Scholar · View at Scopus
  147. D. A. Ribardo, J. W. Peterson, and A. K. Chopra, “Phospholipase A2-activating protein—an important regulatory molecule in modulating cyclooxygenase-2 and tumor necrosis factor production during inflammation,” Indian Journal of Experimental Biology, vol. 40, no. 2, pp. 129–138, 2002. View at Google Scholar · View at Scopus
  148. T. Sassa, S. Suto, Y. Okayasu, and A. Kihara, “A shift in sphingolipid composition from C24 to C16 increases susceptibility to apoptosis in HeLa cells,” Biochimica et Biophysica Acta, vol. 1821, no. 7, pp. 1031–1037, 2012. View at Publisher · View at Google Scholar
  149. M. Hayakawa, N. Ishida, K. Takeuchi et al., “Arachidonic acid-selective cytosolic phospholipase A2 is crucial in the cytotoxic action of tumor necrosis factor,” The Journal of Biological Chemistry, vol. 268, no. 15, pp. 11290–11295, 1993. View at Google Scholar · View at Scopus
  150. Y. Cao, A. T. Pearman, G. A. Zimmerman, T. M. McIntyre, and S. M. Prescott, “Intracellular unesterified arachidonic acid signals apoptosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 21, pp. 11280–11285, 2000. View at Google Scholar · View at Scopus
  151. G. L. Bannenberg, “Therapeutic applicability of anti-inflammatory and proresolving polyunsaturated fatty acid-derived lipid mediators,” TheScientificWorldJOURNAL, vol. 10, pp. 676–712, 2010. View at Publisher · View at Google Scholar · View at Scopus
  152. J. E. Kinsella, “Lipids, membrane receptors, and enzymes: effects of dietary fatty acids,” Journal of Parenteral and Enteral Nutrition, vol. 14, no. 5, pp. 200S–217S, 1990. View at Google Scholar · View at Scopus
  153. V. di Marzo, “Arachidonic acid and eicosanoids as targets and effectors in second messenger interactions,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 53, no. 4, pp. 239–254, 1995. View at Google Scholar · View at Scopus
  154. J. Nowak, K. H. Weylandt, P. Habbel et al., “Colitis-associated colon tumorigenesis is suppressed in transgenic mice rich in endogenous n-3 fatty acids,” Carcinogenesis, vol. 28, no. 9, pp. 1991–1995, 2007. View at Publisher · View at Google Scholar · View at Scopus
  155. H. Sampath and J. M. Ntambi, “Polyunsaturated fatty acid regulation of genes of lipid metabolism,” Annual Review of Nutrition, vol. 25, pp. 317–340, 2005. View at Publisher · View at Google Scholar · View at Scopus
  156. I. J. Edwards and J. T. O'Flaherty, “Omega-3 fatty acids and PPAR γ in cancer,” PPAR Research, vol. 2008, Article ID 358052, 14 pages, 2008. View at Publisher · View at Google Scholar · View at Scopus
  157. S. A. Kliewer, S. S. Sundseth, S. A. Jones et al., “Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 9, pp. 4318–4323, 1997. View at Publisher · View at Google Scholar · View at Scopus
  158. J. Han, R. C. Soletti, A. Sadarangani et al., “Nuclear expression of beta-catenin promotes RB stability and resistance to TNF-induced apoptosis in colon cancer cells,” Molecular Cancer Research, vol. 11, pp. 207–218, 2013. View at Google Scholar
  159. B. A. Narayanan, N. K. Narayanan, B. Simi, and B. S. Reddy, “Modulation of inducible nitric oxide synthase and related proinflammatory genes by the omega-3 fatty acid docosahexaenoic acid in human colon cancer cells,” Cancer Research, vol. 63, no. 5, pp. 972–979, 2003. View at Google Scholar · View at Scopus
  160. A. Hernandez, R. Thomas, F. Smith et al., “Butyrate sensitizes human colon cancer cells to TRAIL-mediated apoptosis,” Surgery, vol. 130, no. 2, pp. 265–272, 2001. View at Publisher · View at Google Scholar · View at Scopus
  161. F. M. Ruemmele, S. Dionne, I. Qureshi, D. S. R. Sarma, E. Levy, and E. G. Seidman, “Butyrate mediates Caco-2 cell apoptosis via up-regulation of pro-apoptotic BAK and inducing caspase-3 mediated cleavage of poly-(ADP-ribose) polymerase (PARP),” Cell Death and Differentiation, vol. 6, no. 8, pp. 729–735, 1999. View at Google Scholar · View at Scopus
  162. S. A. Jones, R. N. Butler, I. R. Sanderson, and J. W. Wilson, “The effect of specific caspase inhibitors on TNF-α and butyrate-induced apoptosis of intestinal epithelial cells,” Experimental Cell Research, vol. 292, no. 1, pp. 29–39, 2004. View at Publisher · View at Google Scholar · View at Scopus
  163. S. Orzechowska, B. Pajak, B. Gajkowska, and A. Orzechowski, “Cholesterol level determines viability and mitogenicity, but it does not affect sodium butyrate-dependent sensitization of Colo 205 cells to TNF-α-induced apoptosis,” Oncology Reports, vol. 25, no. 2, pp. 573–582, 2011. View at Publisher · View at Google Scholar · View at Scopus
  164. S. E. F. Tran, T. H. Holmström, M. Ahonen, V.-M. Kähäri, and J. E. Eriksson, “MAPK/ERK overrides the apoptotic signaling from Fas, TNF, and TRAIL receptors,” The Journal of Biological Chemistry, vol. 276, no. 19, pp. 16484–16490, 2001. View at Publisher · View at Google Scholar · View at Scopus
  165. C. Giardina, H. Boulares, and M. S. Inan, “NSAIDs and butyrate sensitize a human colorectal cancer cell line to TNF-α and Fas ligation: the role of reactive oxygen species,” Biochimica et Biophysica Acta, vol. 1448, no. 3, pp. 425–438, 1999. View at Publisher · View at Google Scholar · View at Scopus
  166. M. Kovaříková, J. Pacherník, J. Hofmanová, Z. Zadák, and A. Kozubík, “TNF-alpha modulates the differentiation induced by butyrate in the HT-29 human colon adenocarcinoma cell line,” European Journal of Cancer, vol. 36, no. 14, pp. 1844–1852, 2000. View at Google Scholar
  167. J. Gong, D. Yang, S. Kohanim, R. Humphreys, L. Broemeling, and R. Kurzrock, “Novel in vivo imaging shows up-regulation of death receptors by paclitaxel and correlates with enhanced antitumor effects of receptor agonist antibodies,” Molecular Cancer Therapeutics, vol. 5, no. 12, pp. 2991–3000, 2006. View at Publisher · View at Google Scholar · View at Scopus
  168. B. Pajak, B. Gajkowska, and A. Orzechowski, “Position of STAT-1α in cycloheximide-dependent apoptosis triggered by TNF-α in human colorectal COLO 205 cancer cell line; role of polyphenolic compounds,” Journal of Physiology and Pharmacology, vol. 56, supplement 3, pp. 119–141, 2005. View at Google Scholar · View at Scopus
  169. M. A. Lombard, T. L. Wallace, M. F. Kubicek et al., “Synthetic matrix metalloproteinase inhibitors and tissue inhibitor of metalloproteinase (TIMP)-2, but not TIMP-1, inhibit shedding of tumor necrosis factor-α receptors in a human colon adenocarcinoma (Colo 205) cell line,” Cancer Research, vol. 58, no. 17, pp. 4001–4007, 1998. View at Google Scholar · View at Scopus
  170. B. Pajak, B. Gajkowska, and A. Orzechowski, “Cycloheximide-mediated sensitization to TNF-α-induced apoptosis in human colorectal cancer cell line COLO 205; role of FLIP and metabolic inhibitors,” Journal of Physiology and Pharmacology, vol. 56, supplement 3, pp. 101–118, 2005. View at Google Scholar · View at Scopus
  171. B. Pajak and A. Orzechowski, “IFN-alpha competes with TNF-alpha for STAT-1alpha; molecular basis for immune escape of human colon adenocarcinoma COLO 205 cells,” Oncology Reports, vol. 18, no. 4, pp. 1039–1045, 2007. View at Google Scholar · View at Scopus
  172. P. Cesaro, E. Raiteri, M. Démoz et al., “Expression of protein kinase C β1 confers resistance to TNFα- and paclitaxel-induced apoptosis in HT-29 colon carcinoma cells,” International Journal of Cancer, vol. 93, no. 2, pp. 179–184, 2001. View at Publisher · View at Google Scholar · View at Scopus
  173. O. C. Velázquez, R. W. Seto, and J. L. Rombeau, “The scientific rationale and clinical application of short-chain fatty acids and medium-chain triacylglycerols,” Proceedings of the Nutrition Society, vol. 55, no. 1, pp. 49–78, 1996. View at Google Scholar · View at Scopus
  174. M. S. Inan, R. J. Rasoulpour, L. Yin, A. K. Hubbard, D. W. Rosenberg, and C. Giardina, “The luminal short-chain fatty acid butyrate modulates NF-κB activity in a human colonic epithelial cell line,” Gastroenterology, vol. 118, no. 4, pp. 724–734, 2000. View at Google Scholar · View at Scopus
  175. L. Yin, G. Laevsky, and C. Giardina, “Butyrate suppression of colonocyte NF-κ B activation and cellular proteasome activity,” The Journal of Biological Chemistry, vol. 276, no. 48, pp. 44641–44646, 2001. View at Publisher · View at Google Scholar · View at Scopus
  176. M. Hýžd’alová, J. Hofmanová, J. Pacherník, A. Vaculová, and A. Kozubík, “The interaction of butyrate with TNF-alpha during differentiation and apoptosis of colon epithelial cells: role of NF-kappaB activation,” Cytokine, vol. 44, pp. 33–43, 2008. View at Google Scholar
  177. J. D. Butzner, R. Parmar, C. J. Bell, and V. Dalal, “Butyrate enema therapy stimulates mucosal repair in experimental colitis in the rat,” Gut, vol. 38, no. 4, pp. 568–573, 1996. View at Google Scholar · View at Scopus
  178. J. P. Segain, D. Raingeard de la Blétière, A. Bourreille et al., “Butyrate inhibits inflammatory responses through NFκB inhibition: implications for Crohn's disease,” Gut, vol. 47, no. 3, pp. 397–403, 2000. View at Publisher · View at Google Scholar · View at Scopus
  179. Y. H. Kim, J. W. Park, J. Y. Lee, and T. K. Kwon, “Sodium butyrate sensitizes TRAIL-mediated apoptosis by induction of transcription from the DR5 gene promoter through Sp1 sites in colon cancer cells,” Carcinogenesis, vol. 25, no. 10, pp. 1813–1820, 2004. View at Publisher · View at Google Scholar · View at Scopus
  180. H. A. Hamed, Y. Yamaguchi, P. B. Fisher, S. Grant, and P. Dent, “Sorafenib and HDAC inhibitors synergize with TRAIL to kill tumor cells,” Journal of Cellular Physiology, vol. 228, no. 10, pp. 1996–2005, 2013. View at Publisher · View at Google Scholar
  181. J. K. Earel Jr., R. L. VanOosten, and T. S. Griffith, “Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells,” Cancer Research, vol. 66, no. 1, pp. 499–507, 2006. View at Publisher · View at Google Scholar · View at Scopus
  182. A. Bangert, S. Cristofanon, I. Eckhardt et al., “Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP,” Oncogene, vol. 31, pp. 4677–4688, 2012. View at Publisher · View at Google Scholar · View at Scopus
  183. C. Giardina and M. S. Inan, “Nonsteroidal anti-inflammatory drugs, short-chain fatty acids, and reactive oxygen metabolism in human colorectal cancer cells,” Biochimica et Biophysica Acta, vol. 1401, no. 3, pp. 277–288, 1998. View at Publisher · View at Google Scholar · View at Scopus
  184. Y. M. Dupertuis, M. M. Meguid, and C. Pichard, “Advancing from immunonutrition to a pharmaconutrition: a gigantic challenge,” Current Opinion in Clinical Nutrition and Metabolic Care, vol. 12, no. 4, pp. 398–403, 2009. View at Publisher · View at Google Scholar · View at Scopus
  185. B. Lands, “A critique of paradoxes in current advice on dietary lipids,” Progress in Lipid Research, vol. 47, no. 2, pp. 77–106, 2008. View at Publisher · View at Google Scholar · View at Scopus
  186. A. Hagi, M. Nakayama, W. Shinzaki, S. Haji, and H. Ohyanagi, “Effects of the ω-6:ω-3 fatty acid ratio of fat emulsions on the fatty acid composition in cell membranes and the anti-inflammatory action,” Journal of Parenteral and Enteral Nutrition, vol. 34, no. 3, pp. 263–270, 2010. View at Publisher · View at Google Scholar · View at Scopus
  187. Y. Y. Han, S. L. Lai, W. J. Ko, C. H. Chou, and H. S. Lai, “Effects of fish oil on inflammatory modulation in surgical intensive care unit patients,” Nutrition in Clinical Practice, vol. 27, no. 1, pp. 91–98, 2012. View at Publisher · View at Google Scholar · View at Scopus
  188. G. J. A. Wanten and P. C. Calder, “Immune modulation by parenteral lipid emulsions,” American Journal of Clinical Nutrition, vol. 85, no. 5, pp. 1171–1184, 2007. View at Google Scholar · View at Scopus
  189. I. M. Berquin, I. J. Edwards, and Y. Q. Chen, “Multi-targeted therapy of cancer by omega-3 fatty acids,” Cancer Letters, vol. 269, no. 2, pp. 363–377, 2008. View at Publisher · View at Google Scholar · View at Scopus
  190. P. C. Calder, “Symposium 4: hot topics in parenteral nutrition. Rationale for using new lipid emulsions in parenteral nutrition and a review of the trials performed in adults,” Proceedings of the Nutrition Society, vol. 68, no. 3, pp. 252–260, 2009. View at Publisher · View at Google Scholar · View at Scopus
  191. D. L. Waitzberg and R. S. Torrinhas, “Fish oil lipid emulsions and immune response: what clinicians need to know,” Nutrition in Clinical Practice, vol. 24, no. 4, pp. 487–499, 2009. View at Publisher · View at Google Scholar · View at Scopus
  192. V. A. van Beelen, B. Spenkelink, H. Mooibroek et al., “An n-3 PUFA-rich microalgal oil diet protects to a similar extent as a fish oil-rich diet against AOM-induced colonic aberrant crypt foci in F344 rats,” Food and Chemical Toxicology, vol. 47, no. 2, pp. 316–320, 2009. View at Publisher · View at Google Scholar · View at Scopus
  193. F. D. Russell and C. S. Burgin-Maunder, “Distinguishing health benefits of eicosapentaenoic and docosahexaenoic acids,” Marine Drugs, vol. 10, pp. 2535–2559, 2012. View at Google Scholar
  194. R. Garib, P. Garla, R. S. Torrinhas, P. L. Bertevello, A. F. Logullo, and D. L. Waitzberg, “Effects of parenteral fish oil lipid emulsions on colon morphology and cytokine expression after experimental colitis,” Nutrición Hospitalaria, vol. 28, no. 3, pp. 849–856, 2013. View at Publisher · View at Google Scholar
  195. M. J. Tisdale, “The ‘cancer cachectic factor’,” Supportive Care in Cancer, vol. 11, no. 2, pp. 73–78, 2003. View at Google Scholar · View at Scopus
  196. B. Pajak, S. Orzechowska, B. Pijet et al., “Crossroads of cytokine signaling—the chase to stop muscle cachexia,” Journal of Physiology and Pharmacology, vol. 59, supplement 9, pp. 251–264, 2008. View at Google Scholar · View at Scopus
  197. C. Deans and S. J. Wigmore, “Systemic inflammation, cachexia and prognosis in patients with cancer,” Current Opinion in Clinical Nutrition and Metabolic Care, vol. 8, no. 3, pp. 265–269, 2005. View at Google Scholar · View at Scopus
  198. F. Balkwill, “TNF-α in promotion and progression of cancer,” Cancer and Metastasis Reviews, vol. 25, no. 3, pp. 409–416, 2006. View at Publisher · View at Google Scholar · View at Scopus
  199. R. Raqib, P. Sarker, A. Mily et al., “Efficacy of sodium butyrate adjunct therapy in shigellosis: a randomized, double-blind, placebo-controlled clinical trial,” BMC Infectious Diseases, vol. 12, article 111, 2012. View at Google Scholar